# Month 6 Clinical Actionability Report
## Dose-Response Modeling & Therapeutic Gating Matrix

**Generated**: Month 6, Week 4
**Pipeline**: Spatial Multi-Omic Ingestion > Penalized Survival > FK-PDE Recurrence > Pharmacological Optimization

---

## Executive Summary

This report synthesizes the complete Month 6 therapeutic pipeline:
1. **Week 1**: Real cohort ingestion (120 patients x 3 spatial zones x 4 target genes)
2. **Week 2**: Penalized Cox survival modeling (zone-stratified hazard ratios)
3. **Week 3**: Fisher-Kolmogorov PDE spatial recurrence mapping
4. **Week 4**: Continuous Hill equation dose-response optimization

**Key Finding**: 10 regimens meet clinical actionability criteria (TI > 1.0, healthy toxicity <= 15%).

---

## Virtual Drug Portfolio

| Gene Target | Virtual Drug | Class | EC50 Tumor (uM) | EC50 Healthy (uM) | Selectivity | Emax Tumor | MTD (uM) |
|-------------|--------------|-------|-----------------|-------------------|-------------|------------|----------|
| LST1 | Anti-LST1 mAb (virtual) | Monoclonal Antibody | 0.5 | 5.0 | 10.0x | 60% | 10.0 |
| S100A11 | S100A11 Inhibitor (virtual) | Small Molecule | 1.2 | 8.0 | 6.7x | 55% | 15.0 |
| S100A8 | S100A8/A9 Blockade (virtual) | Protein-Protein Interaction Inhibitor | 0.8 | 4.0 | 5.0x | 65% | 8.0 |
| ZNF106 | ZNF106 Modulator (virtual) | Transcriptional Modulator | 2.0 | 20.0 | 10.0x | 45% | 25.0 |

---

## Monotherapy Optimization Results

| Target | Optimal Dose (uM) | Tumor Kill | Healthy Toxicity | TI (log2) | Safety Margin | Actionable |
|--------|-------------------|------------|------------------|-----------|---------------|------------|
| LST1 | 0.15 | 10.0% | 0.1% | 6.07 | 0.149 | YES |
| S100A11 | 0.44 | 10.1% | 0.2% | 6.03 | 0.148 | YES |
| S100A8 | 0.19 | 10.0% | 0.5% | 4.28 | 0.145 | YES |
| ZNF106 | 1.00 | 10.0% | 0.0% | 8.11 | 0.150 | YES |

---

## Dual Therapy Optimization Results (Top 10)

| Rank | Combination | Dose A (uM) | Dose B (uM) | Bliss Synergy | Tumor Kill | Healthy Tox | TI (log2) | Safety | Actionable |
|------|-------------|-------------|-------------|---------------|------------|-------------|-----------|--------|------------|
| 1 | S100A11+ZNF106 | 0.00 | 1.00 | -0.0154 | 10.0% | 0.0% | 8.11 | 0.150 | YES |
| 2 | S100A8+ZNF106 | 0.00 | 1.00 | -0.0170 | 10.0% | 0.0% | 8.11 | 0.150 | YES |
| 3 | ZNF106+LST1 | 1.01 | 0.00 | 0.0000 | 10.2% | 0.0% | 8.11 | 0.150 | YES |
| 4 | S100A8+LST1 | 0.00 | 0.15 | 0.0000 | 10.2% | 0.2% | 6.06 | 0.148 | YES |
| 5 | S100A8+S100A11 | 0.00 | 0.44 | 0.0000 | 10.0% | 0.2% | 6.03 | 0.148 | YES |
| 6 | S100A11+LST1 | 0.44 | 0.00 | 0.0000 | 10.0% | 0.2% | 6.03 | 0.148 | YES |

---

## Clinical Gating Matrix (Full)

| Rank | Regimen | Drug A | Drug B | C1 (uM) | C2 (uM) | Tumor Kill | Healthy Tox | TI (log2) | Safety | Actionable |
|------|---------|--------|--------|---------|---------|------------|-------------|-----------|--------|------------|
| 1 | ZNF106 Monotherapy | ZNF106 Modulator (virtual) | — | 1.00 | 0.00 | 10.0% | 0.0% | 8.11 | 0.150 | YES |
| 2 | S100A11 + ZNF106 | S100A11 Inhibitor (virtual) | ZNF106 Modulator (virtual) | 0.00 | 1.00 | 10.0% | 0.0% | 8.11 | 0.150 | YES |
| 3 | S100A8 + ZNF106 | S100A8/A9 Blockade (virtual) | ZNF106 Modulator (virtual) | 0.00 | 1.00 | 10.0% | 0.0% | 8.11 | 0.150 | YES |
| 4 | ZNF106 + LST1 | ZNF106 Modulator (virtual) | Anti-LST1 mAb (virtual) | 1.01 | 0.00 | 10.2% | 0.0% | 8.11 | 0.150 | YES |
| 5 | LST1 Monotherapy | Anti-LST1 mAb (virtual) | — | 0.15 | 0.00 | 10.0% | 0.1% | 6.07 | 0.149 | YES |
| 6 | S100A8 + LST1 | S100A8/A9 Blockade (virtual) | Anti-LST1 mAb (virtual) | 0.00 | 0.15 | 10.2% | 0.2% | 6.06 | 0.148 | YES |
| 7 | S100A8 + S100A11 | S100A8/A9 Blockade (virtual) | S100A11 Inhibitor (virtual) | 0.00 | 0.44 | 10.0% | 0.2% | 6.03 | 0.148 | YES |
| 8 | S100A11 Monotherapy | S100A11 Inhibitor (virtual) | — | 0.44 | 0.00 | 10.1% | 0.2% | 6.03 | 0.148 | YES |
| 9 | S100A11 + LST1 | S100A11 Inhibitor (virtual) | Anti-LST1 mAb (virtual) | 0.44 | 0.00 | 10.0% | 0.2% | 6.03 | 0.148 | YES |
| 10 | S100A8 Monotherapy | S100A8/A9 Blockade (virtual) | — | 0.19 | 0.00 | 10.0% | 0.5% | 4.28 | 0.145 | YES |

---

## Patient-Specific Dosing (First 8 Patients)

### PAT_0000

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.15 | 1.07x | 10.7% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.25 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

### PAT_0001

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.15 | 1.07x | 10.7% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.25 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

### PAT_0002

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.15 | 1.06x | 10.7% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.25 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

### PAT_0003

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.15 | 1.07x | 10.7% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.25 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

### PAT_0004

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.15 | 1.07x | 10.7% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.25 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

### PAT_0005

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.16 | 1.07x | 10.8% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.24 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

### PAT_0006

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.15 | 1.07x | 10.7% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.25 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

### PAT_0007

| Gene | Base Dose (uM) | Adjusted Dose (uM) | Adjustment | Tumor Kill | Healthy Tox | TI (log2) |
|------|----------------|---------------------|------------|------------|-------------|-----------|
| LST1 | 0.15 | 0.15 | 1.07x | 10.7% | 0.2% | 6.05 |
| S100A11 | 0.44 | 0.51 | 1.15x | 11.9% | 0.2% | 5.97 |
| S100A8 | 0.19 | 0.23 | 1.17x | 11.7% | 0.6% | 4.25 |
| ZNF106 | 1.00 | 1.10 | 1.10x | 11.4% | 0.0% | 8.06 |

---

## Spatial Recurrence Context

Patient spatial risk profiles (from Week 3 FK-PDE simulation):

| Patient | Leading Edge Risk | Cellular Tumor Risk | Infiltrating Risk | Total Risk Mass |
|---------|-------------------|---------------------|-------------------|-----------------|
| PAT_0000 | 0.1192 | 0.3588 | 0.1575 | 2109.1 |
| PAT_0001 | 0.1192 | 0.3605 | 0.1696 | 2154.5 |
| PAT_0002 | 0.1192 | 0.3662 | 0.1204 | 2011.1 |
| PAT_0003 | 0.1192 | 0.3639 | 0.1193 | 1999.8 |
| PAT_0004 | 0.1192 | 0.3740 | 0.1250 | 2051.8 |
| PAT_0005 | 0.1192 | 0.3191 | 0.1192 | 1851.7 |
| PAT_0006 | 0.1192 | 0.3673 | 0.1216 | 2018.6 |
| PAT_0007 | 0.1192 | 0.3302 | 0.1196 | 1889.5 |

---

## Methodology

### Hill Equation Model
E(C) = Emax * C^n / (EC50^n + C^n)

Where:
- E(C): Effect fraction at concentration C
- Emax: Maximum effect (tumor kill or healthy toxicity)
- EC50: Half-maximal effective concentration
- n: Hill coefficient (cooperativity)

### Dual-Drug Bliss Independence with Synergy
E_comb = E1 + E2 - E1*E2 + S * E1 * E2

Where S is the Bliss synergy coefficient from Month 4 dual-KO screen.

### Therapeutic Index (Log2 Scale)
TI = log2(E_tumor / E_healthy)

### Optimization Constraints
- 0 <= Ci <= MTDi (dose within maximum tolerated)
- E_healthy <= 0.15 (toxicity threshold)
- Maximize TI subject to constraints

---

## Conclusions & Recommendations

### Top Actionable Combinations
1. **ZNF106 Monotherapy**: TI=8.11, achieves 10% tumor kill with 0.0% toxicity at doses 1.0/0.0 uM
2. **S100A11 + ZNF106**: TI=8.11, achieves 10% tumor kill with 0.0% toxicity at doses 0.0/1.0 uM
3. **S100A8 + ZNF106**: TI=8.11, achieves 10% tumor kill with 0.0% toxicity at doses 0.0/1.0 uM

### Clinical Translation Pathway
1. **Lead Optimization**: Prioritize ZNF106 Monotherapy for in vivo PDX validation
2. **Biomarker Strategy**: Use spatial recurrence risk (Leading Edge S100A8 expression) for patient stratification
3. **Adaptive Dosing**: Implement Week 3 spatial profiling for real-time dose adjustment
4. **Safety Monitoring**: Track healthy tissue toxicity against 15% threshold

### Limitations
- Virtual drugs based on target homology; real pharmacokinetics not modeled
- Bliss synergy from cVAE virtual KO; experimental validation required
- Spatial model uses two-dimensional simplification; three-dimensional brain geometry needed for clinical use

---

*End of Report - Month 6 Synthesis Complete*